Supply Chain Intelligence

Aquestive Therapeutics, Inc. Supply Chain

AQST supply chain intelligence for Aquestive Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

AQST ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
9Customers
2Debt Items
18Related Chains

Aquestive Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
OAKTREE-FUND-ADMINISTRATION-LLC OAKTREE-FUND-ADMINISTRATION-LLC 92% the Company entered into a five-year term loan facility with certain funds managed by each of Oaktree Capital Management, L.P. party thereto (collectively, the “Lenders”).
RTW-INVESTMENTS-LP RTW-INVESTMENTS-LP 90% the Company entered into an intercreditor agreement with the Purchaser under the purchase and sale agreement dated August 13, 2025, as amended (the “Purchase Agreement”) with funds managed by RTW Inv…
THIRD-PARTIES THIRD-PARTIES 90% each of which agreements requires the Company to make payments to each counterparty thereof, respectively, of a portion of our revenues
U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION 90% the Company repaid in full the existing outstanding indebtedness owed by the Company to the noteholders under an indenture with U.S. Bank Trust Company, National Association

Aquestive Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
LICENSEES LICENSEES 92% The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents
COSETTE COSETTE 90% Under that Asset Purchase Agreement, Assertio assigned and transferred its rights and certain obligations arising post closing to Cosette. Cosette assumed the intellectual property license and rights…
INDIVIOR INDIVIOR 90% For the three months ended March 31, 2026, Indivior and Zevra, represented approximately 57 % and 32 %, of total revenue, respectively.
ZEVRA ZEVRA 90% For the three months ended March 31, 2026, Indivior and Zevra, represented approximately 57 % and 32 %, of total revenue, respectively.
ASRT Assertio Holdings, Inc. 85% anovia Amendment No. 1, we received a non-refundable payment of $2,000 from Pharmanovia on execution of the Pharmanovia Amendment No. 1. • Sympazan ® – an oral soluble film formulation of clobazam us…
ASRT Assertio Holdings, Inc. 85% Reciprocal relationship from ASRT graph: Reciprocal relationship from AQST graph: Reciprocal relationship from ASRT graph: Reciprocal relationship from AQST graph: Reciprocal relationship from ASRT g…
ASSERTIO ASSERTIO 85% As of March 31, 2026, Indivior and Assertio exceeded the 10% threshold for outstanding receivable balances and represented approximately 81 % and 15 % of total trade and other receivables, respectively.
HYPERA HYPERA 85% For the three months ended March 31, 2025, Indivior and Hypera exceeded the 10% threshold for revenue and represented approximately 67 % and 17 % of total revenue, including the one-time recognition …
ZVRA Zevra Therapeutics, Inc. 85% Reciprocal relationship from ZVRA graph: Under our March 2012 termination agreement with Aquestive Therapeutics, Aquestive has the right to receive a royalty amount equal to 10% of any value generate…

Aquestive Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
AQST-DEBT-7821 Warrants outstanding: 375000 90% xbrl warrant detail from xbrl 2026-03-03.
AQST-DEBT Debt stack $43.6M 90% Market cache reports total debt of $43.6M.

Aquestive Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Aquestive Therapeutics, Inc..

Aquestive Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
AQST-OWNER-BRATTON-CAPITAL-MANAGEMENT-L-P Bratton Capital Management, L.P. 90% 13F overlay lists Bratton Capital Management, L.P. as top holder; 181 tracked holders.

Aquestive Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SUPN Supernus Pharmaceuticals, Inc. 100.00 2
LADX LadRx Corporation 100.00 2
NSRX Nasus Pharma Ltd. 100.00 2
NVSEF Novartis AG 100.00 2
ZEVRA ZEVRA 60.75 1 ['receiving']
HYPERA HYPERA 54.19 1 ['receiving']
ZVRA Zevra Therapeutics, Inc. 50.57 1 ['customer']
AYTU Aytu BioPharma, Inc. 50.00 2
AMRX Amneal Pharmaceuticals, Inc. 50.00 2
ORANY ORANGE 50.00 2
ATR AptarGroup, Inc. 50.00 2
MYGN Myriad Genetics, Inc. 50.00 2
XOMA XOMA Royalty Corporation 50.00 2
XOMAP XOMA Royalty Corporation 50.00 2
RELIEF RELIEF 50.00 2
ASRT Assertio Holdings, Inc. 45.90 1 ['customer']
SPRY ARS Pharmaceuticals, Inc. 36.29 1 ['spend']
ALK Alaska Air Group, Inc. 24.13 2
View AQST supply chain intel →

Explore the full interactive supply chain map for Aquestive Therapeutics, Inc..

Open AQST supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map